Vitrolife ABCHIX:VITRS 80 PB Ratio is 1.78 as of Jul. 08, 2026, which is 81% below its 10-year median of 9.38. GuruFocus rates CHIX:VITRS with a GF Score™ of 80/100 and a GF Value™ of kr163.33 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 787 Medical Devices & Instruments companies, Vitrolife AB ranks better than 64.17% on this metric.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. As of today (2026-07-08), Vitrolife AB's share price is kr105.75. Vitrolife AB's Book Value per Share for the quarter that ended in Mar. 2026 was kr59.57. Hence, Vitrolife AB's PB Ratio of today is 1.78.
The historical rank and industry rank for Vitrolife AB's PB Ratio or its related term are showing as below:
CHIX:VITRs'
s PB Ratio Range Over the Past 10 Years
Min: 0.99 Med: 9.38 Max: 26.3
Current: 1.53
During the past 13 years, Vitrolife AB's highest PB Ratio was 26.30. The lowest was 0.99. And the median was 9.38.
CHIX:VITRs's PB Ratio is ranked better than 64.17% of 787
companies
in the Medical Devices & Instruments industry
Industry Median: 2.06
vs CHIX:VITRs: 1.53
During the past 12 months, Vitrolife AB's average Book Value Per Share Growth Rate was -38.50% per year.
During the past 3 years, the average Book Value Per Share Growth Rate was -22.20% per year.
During the past 5 years, the average Book Value Per Share Growth Rate was 15.70% per year.
During the past 10 years, the average Book Value Per Share Growth Rate was 34.10% per year.
During the past 13 years, the highest 3-Year average Book Value Per Share Growth Rate of Vitrolife AB was 101.90% per year. The lowest was -22.20% per year. And the median was 16.60% per year.
The PB Ratio works the best for the businesses that earn most of their profit from their assets, e.g. banks and insurance companies.
Be Aware
Some businesses have very light assets, such as software companies or insurance agencies. The PB Ratio does not work well for these companies. Some companies even have negative equity, so the PB Ratio cannot be applied to them.
Vitrolife AB PB Ratio Related Terms
Vitrolife AB PB Ratio Historical Data
* Premium members only.
The historical data trend for Vitrolife AB's PB Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Vitrolife AB's PB Ratio, along with its competitors' market caps and PB Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vitrolife AB PB Ratio vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Vitrolife AB's PB Ratio distribution charts can be found below:
* The bar in red indicates where Vitrolife AB's PB Ratio falls into.
The PB Ratio, or Price-to-Book ratio, or Price/Book, is a financial ratio used to compare a company's market price to its Book Value per Share. It is a ratio widely used to value stocks.
Vitrolife AB's PB Ratio for today is calculated as follows:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
A closely related ratio is called Price-to-Tangible-Book. The difference between Price-to-Tangible-Book and PB Ratio is that book value other than intangibles are used in the calculation.
Vitrolife AB (CHIX:VITRS) has a PB Ratio of 1.78 as of Jul. 08, 2026. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Vitrolife AB and its competitors. This is 81% below median its historical median of 9.38. Over the past decade, Vitrolife AB's PB Ratio has ranged from 0.99 to 26.30. According to the industry distribution chart, Vitrolife AB ranks #282 out of 787 companies in the Medical Devices & Instruments industry, placing it in the top 35.8%.
Is Vitrolife AB's PB Ratio too high?
Vitrolife AB's current PB Ratio of 1.78 is 81% below median its 10-year median of 9.38. Over the past 10 years, this metric has ranged from a low of 0.99 to a high of 26.30. The Medical Devices & Instruments industry median PB Ratio is 2.06. Vitrolife AB's value of 1.78 is 13.6% below this industry median. Based on the distribution chart, Vitrolife AB ranks #282 out of 787 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Vitrolife AB has a GF Score™ of 80/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Vitrolife AB's PB Ratio compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Vitrolife AB ranks #282 out of 787 companies for PB Ratio. This puts Vitrolife AB in the upper half of its industry. The industry median PB Ratio is 2.06. Vitrolife AB's value of 1.78 is 13.6% below this benchmark. Historically, Vitrolife AB's own PB Ratio has ranged from 0.99 to 26.30 over the past decade. While the company's 10-year median is 9.38 vs. the industry median of 2.06, Vitrolife AB has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PB Ratio for a Medical Devices & Instruments company?
The median PB Ratio among Medical Devices & Instruments companies is 2.06, based on 787 companies in the industry. Companies in the top quartile (top 25%) have a PB Ratio significantly above this median, while those in the bottom quartile fall well below. However, PB Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vitrolife AB's current PB Ratio of 1.78 is 13.6% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PB Ratio mean?
A high PB Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Book ratio is the ratio of share price to a company's book value per share. View historical data on Vitrolife AB and its competitors. For the Medical Devices & Instruments industry, the median PB Ratio is 2.06 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vitrolife AB's current PB Ratio is 1.78, which is 81% below median its own 10-year median of 9.38. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vitrolife AB stock overvalued right now?
Based on GuruFocus' analysis, Vitrolife AB (CHIX:VITRS) is currently considered Possible Value Trap. The stock's GF Value™ is kr163.33, compared to a current price of kr105.75 — trading 35.3% below its estimated fair value. The current PB Ratio is 1.78, which is 81% below median its 10-year median of 9.38 and 13.6% below the Medical Devices & Instruments industry median of 2.06. Vitrolife AB's overall GF Score™ is 80/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PB Ratio calculated?
PB Ratio is calculated from a company's financial statements. For Vitrolife AB (CHIX:VITRS), the current PB Ratio is 1.78 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vitrolife AB (CHIX:VITRS) Overvalued in 2026?
Based on GuruFocus' analysis, Vitrolife AB stock appears to be undervalued.
The current stock price of kr105.75 is trading 35.3% below its estimated GF Value™ of kr163.33.
GuruFocus considers Vitrolife AB to be Possible Value Trap.
Key valuation signals for CHIX:VITRS:
PB Ratio: 1.78 (81% below median its 10-year median of 9.38)
GF Value™: kr163.33 vs. price of kr105.75 (35.3% below fair value)
Industry Position: 13.6% below the Medical Devices & Instruments median (#282 of 787)
No single metric tells the full story. See the CHIX:VITRS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vitrolife AB provides medical devices and genetic testing services intended for the reproductive-health market in the field of reproductive health. The company develops, manufactures, and distributes medical devices and provides genetic testing services for IVF clinics and their patients. Its mission is to support IVF clinics (in vitro fertilization) in enhancing their practice as well as the outcome of a patient's fertility treatment, thereby enabling patients to receive support to navigate the complexities of reproductive health through successful outcomes and patient satisfaction. The company has three geographical segments EMEA, Americas and APAC, out of which it derives maximum revenue from EMEA.
80GF Score
Get the complete analysis for CHIX:VITRS
PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:VITRS has been successfully added to your 
